Search

Zinc acetate

Cefroxadine

Cefroxadine is an orally available cephalosporin antibiotic. As part of its drug class, it shares structural properties to cefalexin as well as its activity spectrum. It was used in Italy but has since been withdrawn.

Tromethamine

It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used

Teplizumab

Teplizumab was designed as an Fc-non-binding antibody in order to reduce the incidence of CRS. … [L44091] Fc-receptors can bind to the "tail-end" anti-CD3 antibodies in an antigen-non-specific manner and lead to severe adverse effects related to cytokine release syndrome (CRS).

Polysorbate 80

A substance that would not normally dissolve in a particular solution is able to dissolve with the use of a solubilizing agent. … with ethylene oxide, is used in many foreign countries, including the U.S. and the EU, where it acts as an emulsifier, a solubilizer in many foods, including bread, cake mix, salad dressing, shortening oil

Atractylodes japonica root oil

Atractylodes japonica root oil is obtained from the roots of Atractylodes japonica, which is a herb native to eastern Asia.

Carbinoxamine

The product label for carbinoxamine as an over the counter cough and cold medicine is being modified to state "do not use" in children under 4 years of age in order to prevent and reduce misuse, as many

Damoctocog alfa pegol

In order to extend half-lives, techniques such as fusion to protein conjugates (Fc part of IgG1 or albumin), chemical modification (PEGylation), and protein sequence modification have been utilized.

Galcanezumab

Galcanezumab is a humanized monoclonal antibody developed by Eli Lilly and Company against human calcitonin gene-related peptide (CGRP). Although several small-molecule CGRP receptor antagonists have been developed, humanized monoclonal ...

Cabozantinib

Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2...